Rank amateur. Beginner. Newbie. Tyro. Whatever the term, I walked into Dendreon like I was making my first ever online trade. It’s a wonder I made any money at all, but wound up making lots of it, in spite of myself.
For new readers of this rag, you should know that I’ve been trading online since [...]
Entries Tagged as 'DNDN'
DNDN: What was I Thinking?
April 29th, 2010 · 2 Comments · Runaway Trading, Stock Trading
This Market – and my Mind – Wanders
April 18th, 2010 · No Comments · Runaway Trading, Stock Trading
Frankly, I had expected better things from this earnings season. Sure, the quarterly confessions of many companies are better, but better or not, they’re not moving the needle on my cash flow meter.
Monday may change all that. I expecting some sort of bounce-back from the Goldman Sachs fiasco and the shellacking it gave my holdings, [...]
Tags: AAPL·DNDN·GE·Runaway Trader·stock earnings
DNDN? Hold ‘em or Fold ‘em
April 14th, 2010 · No Comments · Runaway Trading, Stock Trading
I put a Post-It note on DNDN’s message board today in response to a group of posters embroiled in a brouhaha because Ameritrade raised its margin requirements on this stock, which, in turn, resulted in a broad discussion of the whole notion of betting only so many dollars as you can afford to lose.
The fellow [...]
The DNDN Update: We’re Slipping into the Doldrums
April 13th, 2010 · 2 Comments · Runaway Trading, Stock Trading
You know about Doldrums, don’t you? That’s a famous belt of calms and light winds between the northern and southern trade winds of the Atlantic and Pacific. It’s a notorious place where three-masters of yore became becalmed for days, even weeks, trapping sailors who couldn’t find enough wind to escape the tropical prison.
Any way, now [...]
Tags: DNDN
Anybody Here Taking the “Big Plunge” on DNDN?
April 6th, 2010 · 3 Comments · Runaway Trading, Stock Trading
This Stock Could Buy You Your Own ‘Round-the-World Runaway
It looks like a sure thing. Nearly every Internet report I’m reading about Dendreon (DNDN) suggests that the FDA will soon announce approval of its prostate cancer drug, Provenge, (here’s a sample) and the word on the street is that its share price will bounce $10 or [...]
